Cftr Trikafta denied for missing prior authorization by Humana?

Humana's specific coverage criteria for cftr trikafta are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Requires Prior Authorization for Trikafta

Trikafta (elexacaftor/tezacaftor/ivacaftor) is a specialty-tier medication that Humana requires prior authorization (PA) for before covering a fill. This is a standard utilization-management step for high-cost specialty drugs, not a clinical judgment that the drug is inappropriate for you. A denial for "prior auth required" means either the PA was never submitted, it was submitted with incomplete information, it was denied on clinical grounds after review, or a previously approved PA has lapsed. Understanding which of these applies determines your immediate next step.

## Why It Is Appealable

If the PA was denied on clinical grounds, that determination is a formal adverse benefit determination and is fully appealable under your plan's appeals process and federal law. If the PA was never submitted or was administratively incomplete, the fix is to complete the submission — but if you have already paid out of pocket, request a retrospective review. Federal regulations require that PA decisions be made within defined timeframes and that any denial include a specific clinical rationale you can rebut.

## Federal Appeal Framework

• Internal appeal (Level 1): File within the deadline on your EOB. Humana must decide within 30 days (pre-service, non-urgent) or 72 hours (urgent/expedited). For a patient with active cystic fibrosis, your specialist can typically document medical urgency to support the expedited track.
• Continuation of therapy: If Trikafta was previously covered and this denial interrupts an ongoing course, request continuation-of-care or ongoing authorization review simultaneously with your appeal.
• External review (ACA §2719 / ERISA §503): After exhausting internal appeals, you have approximately 4 months to request an IRO review. Expedited external review is available when delay would seriously jeopardize your health.

## Documentation to Gather

1. Humana's PA criteria for Trikafta — download from Humana's provider or member portal; map every listed requirement to a document in your chart before writing the appeal. 2. Certified CFTR genotype report — confirms your mutation falls within the FDA-approved indication. 3. CF diagnosis records — pulmonologist or CF care center notes documenting diagnosis, current clinical status, and pulmonary function trajectory. 4. Prior-treatment history — dates and outcomes for any prior CF therapies, particularly earlier CFTR modulators, to satisfy any step-therapy component of the PA criteria. 5. Prescriber medical-necessity letter — your CF specialist should address each PA criterion explicitly, cite the FDA-approved prescribing label, reference applicable Cystic Fibrosis Foundation treatment guidelines (by organization name), and document why Trikafta is medically necessary for your specific clinical and genetic profile. 6. PA submission confirmation — if the PA was submitted and Humana did not respond within the required timeframe, document the submission date and any reference numbers; a deemed denial due to non-response is itself appealable.

## Criteria-Mapping Structure

| Humana PA Criterion (from policy) | Supporting Document | |---|---| | Confirmed CF diagnosis | CF center note, [provider], [date] | | Eligible CFTR mutation | Certified lab report, [lab], [date] | | Prescriber is appropriate specialist | Prescriber credentials/NPI on PA form | | Step-therapy satisfied (if required) | Prior-treatment records with dates and outcomes | | Clinical severity documented | Spirometry trend, exacerbation history |

Complete every row. An unanswered criterion is the most common reason an internal appeal fails and an otherwise winnable case goes to external review unnecessarily.